Announcement • May 19
China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 08, 2026 China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 08, 2026, at 09:00 China Standard Time. Location: The Company's Meeting Room, Beijing China Reported Earnings • Apr 25
First quarter 2026 earnings released: EPS: CN¥0.47 (vs CN¥0.49 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.47 (down from CN¥0.49 in 1Q 2025). Revenue: CN¥2.81b (down 8.8% from 1Q 2025). Net income: CN¥484.9m (down 4.3% from 1Q 2025). Profit margin: 17% (in line with 1Q 2025). Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Mar 30
China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Q1, 2026 Results on Apr 25, 2026 China Resources Double-Crane Pharmaceutical Co.,Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026 Reported Earnings • Mar 24
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥1.60 (up from CN¥1.58 in FY 2024). Revenue: CN¥11.0b (down 1.9% from FY 2024). Net income: CN¥1.65b (up 1.2% from FY 2024). Profit margin: 15% (in line with FY 2024). Revenue missed analyst estimates by 5.4%. Earnings per share (EPS) also missed analyst estimates by 4.8%. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Feb 04
Now 20% overvalued Over the last 90 days, the stock has fallen 3.2% to CN¥18.66. The fair value is estimated to be CN¥15.52, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years. Earnings per share has grown by 11%. Revenue is forecast to grow by 14% in 2 years. Earnings are forecast to grow by 25% in the next 2 years. Buy Or Sell Opportunity • Jan 09
Now 20% overvalued Over the last 90 days, the stock has fallen 2.7% to CN¥18.65. The fair value is estimated to be CN¥15.52, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years. Earnings per share has grown by 11%. Revenue is forecast to grow by 14% in 2 years. Earnings are forecast to grow by 25% in the next 2 years. Announcement • Dec 26
China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Fiscal Year 2025 Results on Mar 20, 2026 China Resources Double-Crane Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2025 results on Mar 20, 2026 Buy Or Sell Opportunity • Nov 25
Now 20% overvalued Over the last 90 days, the stock has fallen 4.7% to CN¥18.68. The fair value is estimated to be CN¥15.52, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years. Earnings per share has grown by 11%. Revenue is forecast to grow by 14% in 2 years. Earnings are forecast to grow by 25% in the next 2 years. Declared Dividend • Oct 27
Dividend of CN¥0.10 announced Dividend of CN¥0.10 is the same as last year. Ex-date: 28th October 2025 Payment date: 28th October 2025 Dividend yield will be 2.5%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (24% earnings payout ratio) and cash flows (50% cash payout ratio). The dividend has increased by an average of 16% per year over the past 9 years. However, payments have been volatile during that time. EPS is expected to grow by 20% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Oct 25
Third quarter 2025 earnings released: EPS: CN¥0.36 (vs CN¥0.34 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.36 (up from CN¥0.34 in 3Q 2024). Revenue: CN¥2.54b (down 3.0% from 3Q 2024). Net income: CN¥374.0m (up 6.7% from 3Q 2024). Profit margin: 15% (up from 13% in 3Q 2024). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Q3, 2025 Results on Oct 25, 2025 China Resources Double-Crane Pharmaceutical Co.,Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025 Reported Earnings • Aug 25
Second quarter 2025 earnings released: EPS: CN¥0.46 (vs CN¥0.61 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.46 (down from CN¥0.61 in 2Q 2024). Revenue: CN¥2.66b (down 14% from 2Q 2024). Net income: CN¥468.8m (down 26% from 2Q 2024). Profit margin: 18% (down from 20% in 2Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Jul 29
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 5.7% to CN¥19.94. The fair value is estimated to be CN¥16.28, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.4% over the last 3 years. Earnings per share has grown by 20%. Revenue is forecast to grow by 10% in 2 years. Earnings are forecast to grow by 18% in the next 2 years. Declared Dividend • Jul 09
Dividend of CN¥0.37 announced Shareholders will receive a dividend of CN¥0.37. Ex-date: 11th July 2025 Payment date: 11th July 2025 Dividend yield will be 2.5%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is well covered by both earnings (30% earnings payout ratio) and cash flows (44% cash payout ratio). The dividend has increased by an average of 16% per year over the past 9 years. However, payments have been volatile during that time. EPS is expected to grow by 25% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Jun 30
China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report First Half, 2025 Results on Aug 23, 2025 China Resources Double-Crane Pharmaceutical Co.,Ltd. announced that they will report first half, 2025 results on Aug 23, 2025 Buy Or Sell Opportunity • Jun 03
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 4.1% to CN¥19.74. The fair value is estimated to be CN¥16.28, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.4% over the last 3 years. Earnings per share has grown by 20%. Revenue is forecast to grow by 10% in 2 years. Earnings are forecast to grow by 18% in the next 2 years. Reported Earnings • Apr 26
First quarter 2025 earnings released: EPS: CN¥0.49 (vs CN¥0.41 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.49 (up from CN¥0.41 in 1Q 2024). Revenue: CN¥3.08b (up 8.6% from 1Q 2024). Net income: CN¥506.7m (up 22% from 1Q 2024). Profit margin: 17% (up from 15% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Announcement • Apr 26
China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 16, 2025 China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 16, 2025, at 09:00 China Standard Time. Location: 9F, Block A, Ruichuang International Center, Chaoyang District, Beijing China Announcement • Mar 28
China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Q1, 2025 Results on Apr 26, 2025 China Resources Double-Crane Pharmaceutical Co.,Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025 Reported Earnings • Mar 21
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥1.58 (up from CN¥1.30 in FY 2023). Revenue: CN¥11.2b (up 9.7% from FY 2023). Net income: CN¥1.63b (up 22% from FY 2023). Profit margin: 14% (up from 13% in FY 2023). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 5.8%. Earnings per share (EPS) also missed analyst estimates by 5.2%. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Announcement • Dec 27
China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Fiscal Year 2024 Results on Mar 20, 2025 China Resources Double-Crane Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2024 results on Mar 20, 2025 Reported Earnings • Oct 27
Third quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.29 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.34 (up from CN¥0.29 in 3Q 2023). Revenue: CN¥2.62b (up 13% from 3Q 2023). Net income: CN¥350.5m (up 17% from 3Q 2023). Profit margin: 13% (in line with 3Q 2023). Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 28% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Sep 30
China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 26, 2024 China Resources Double-Crane Pharmaceutical Co.,Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to CN¥23.82, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total returns to shareholders of 119% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥44.01 per share. Major Estimate Revision • Aug 29
Consensus EPS estimates increase by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from CN¥11.4b to CN¥11.9b. EPS estimate increased from CN¥1.46 to CN¥1.62 per share. Net income forecast to grow 26% next year vs 30% growth forecast for Pharmaceuticals industry in China. Consensus price target broadly unchanged at CN¥25.80. Share price rose 13% to CN¥21.00 over the past week. Declared Dividend • Jul 11
Dividend of CN¥0.26 announced Shareholders will receive a dividend of CN¥0.26. Ex-date: 15th July 2024 Payment date: 15th July 2024 Dividend yield will be 1.4%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is well covered by both earnings (19% earnings payout ratio) and cash flows (22% cash payout ratio). The dividend has increased over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 36% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Announcement • Jun 28
China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 23, 2024 China Resources Double-Crane Pharmaceutical Co.,Ltd. announced that they will report first half, 2024 results on Aug 23, 2024 Announcement • Apr 29
China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024 China Resources Double-Crane Pharmaceutical Co.,Ltd., Annual General Meeting, May 17, 2024, at 09:30 China Standard Time. Location: The Company's Meeting Room, Beijing China Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥0.41 (vs CN¥0.36 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.41 (up from CN¥0.36 in 1Q 2023). Revenue: CN¥2.84b (up 3.5% from 1Q 2023). Net income: CN¥416.1m (up 12% from 1Q 2023). Profit margin: 15% (up from 14% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 21% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Mar 29
China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024 China Resources Double-Crane Pharmaceutical Co.,Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Reported Earnings • Mar 23
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: EPS: CN¥1.30 (up from CN¥1.12 in FY 2022). Revenue: CN¥10.2b (up 8.2% from FY 2022). Net income: CN¥1.33b (up 15% from FY 2022). Profit margin: 13% (in line with FY 2022). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) exceeded analyst estimates by 2.4%. Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. Buy Or Sell Opportunity • Jan 19
Now 20% undervalued Over the last 90 days, the stock has risen 14% to CN¥17.31. The fair value is estimated to be CN¥21.71, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.1% over the last 3 years. Earnings per share has grown by 8.1%. Revenue is forecast to grow by 39% in 2 years. Earnings are forecast to grow by 45% in the next 2 years. Announcement • Dec 29
China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024 China Resources Double-Crane Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2023 results on Mar 22, 2024 Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥0.24 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.29 (up from CN¥0.24 in 3Q 2022). Revenue: CN¥2.31b (up 2.9% from 3Q 2022). Net income: CN¥301.0m (up 24% from 3Q 2022). Profit margin: 13% (up from 11% in 3Q 2022). Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 8% per year whereas the company’s share price has increased by 10% per year. Reported Earnings • Aug 24
Second quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.40 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.39 (down from CN¥0.40 in 2Q 2022). Revenue: CN¥2.50b (up 4.3% from 2Q 2022). Net income: CN¥404.4m (flat on 2Q 2022). Profit margin: 16% (in line with 2Q 2022). Revenue is forecast to grow 7.7% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 5% per year. Price Target Changed • May 15
Price target increased by 26% to CN¥24.32 Up from CN¥19.26, the current price target is provided by 1 analyst. New target price is 30% above last closing price of CN¥18.72. Stock is down 36% over the past year. The company is forecast to post earnings per share of CN¥1.27 for next year compared to CN¥1.12 last year. Valuation Update With 7 Day Price Move • Apr 27
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥21.56, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 22x in the Pharmaceuticals industry in China. Total returns to shareholders of 84% over the past three years. Reported Earnings • Mar 29
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2022 results: EPS: CN¥1.12 (up from CN¥0.90 in FY 2021). Revenue: CN¥9.45b (up 3.7% from FY 2021). Net income: CN¥1.16b (up 24% from FY 2021). Profit margin: 12% (up from 10% in FY 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 5.8%. Earnings per share (EPS) exceeded analyst estimates by 5.0%. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥18.15, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total returns to shareholders of 52% over the past three years. Valuation Update With 7 Day Price Move • Dec 13
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥23.81, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 105% over the past three years. Price Target Changed • Nov 16
Price target increased to CN¥19.26 Up from CN¥16.00, the current price target is provided by 1 analyst. New target price is approximately in line with last closing price of CN¥19.93. Stock is up 70% over the past year. The company is forecast to post earnings per share of CN¥1.07 for next year compared to CN¥0.90 last year. Board Change • Nov 16
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Director Ning Liu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.28 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.24 (down from CN¥0.28 in 3Q 2021). Revenue: CN¥2.25b (flat on 3Q 2021). Net income: CN¥242.0m (down 18% from 3Q 2021). Profit margin: 11% (down from 13% in 3Q 2021). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 13% per year, which means it is well ahead of earnings. Reported Earnings • Aug 24
Second quarter 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.30 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.40 (up from CN¥0.30 in 2Q 2021). Revenue: CN¥2.39b (up 7.7% from 2Q 2021). Net income: CN¥404.7m (up 31% from 2Q 2021). Profit margin: 17% (up from 14% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 9.8%, compared to a 23% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Jul 28
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥21.65, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 84% over the past three years. Board Change • Jul 13
Less than half of directors are independent There are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 independent directors. 7 non-independent directors. Independent Director Ning Liu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Valuation Update With 7 Day Price Move • Jul 01
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥27.09, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 125% over the past three years. Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment deteriorated over the past week After last week's 33% share price decline to CN¥22.57, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total returns to shareholders of 104% over the past three years. Valuation Update With 7 Day Price Move • May 18
Investor sentiment deteriorated over the past week After last week's 20% share price decline to CN¥27.97, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total returns to shareholders of 127% over the past three years. Reported Earnings • May 04
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: CN¥0.32 (up from CN¥0.27 in 1Q 2021). Revenue: CN¥2.52b (up 4.6% from 1Q 2021). Net income: CN¥332.0m (up 16% from 1Q 2021). Profit margin: 13% (up from 12% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 5.4%. Earnings per share (EPS) also missed analyst estimates by 15%. Over the next year, revenue is forecast to grow 9.7%, compared to a 25% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 32% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Apr 29
Investor sentiment improved over the past week After last week's 33% share price gain to CN¥30.11, the stock trades at a forward P/E ratio of 31x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total returns to shareholders of 126% over the past three years. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. 3 independent directors (8 non-independent directors). Board Chairman Emeritus Junfeng Qiao was the last director to join the board, commencing their role in 2003. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment improved over the past week After last week's 23% share price gain to CN¥19.11, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 22x in the Pharmaceuticals industry in China. Total returns to shareholders of 41% over the past three years. Buying Opportunity • Apr 01
Now 21% undervalued Over the last 90 days, the stock is up 23%. The fair value is estimated to be CN¥21.02, however this is not to be taken as a buy recommendation but rather should be used as a guide only. For the next 3 years, revenue is forecast to grow by 7.5% per annum. Earnings is also forecast to grow by 7.9% per annum over the same time period. Valuation Update With 7 Day Price Move • Mar 24
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥14.14, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 24x in the Pharmaceuticals industry in China. Total returns to shareholders of 14% over the past three years. Announcement • Dec 28
China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) announces an Equity Buyback for 23,500,000 shares, for CNY 431.7 million. China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) announces a share repurchase program. Under the program, the company will repurchase up to 23,500,000 shares. The shares will be repurchased at a price of not more than CNY 18.37 per share. The shares purchased will be used for equity incentive plan. The program will be funded out of the company's own funds. The program will be valid till 12 months. Reported Earnings • Nov 01
Third quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.31 in 3Q 2020) The company reported a poor third quarter result with weaker earnings and profit margins, although revenues were flat. Third quarter 2021 results: Revenue: CN¥2.25b (flat on 3Q 2020). Net income: CN¥294.4m (down 7.7% from 3Q 2020). Profit margin: 13% (down from 14% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 24
Second quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.27 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: CN¥2.22b (up 13% from 2Q 2020). Net income: CN¥308.4m (up 10% from 2Q 2020). Profit margin: 14% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 29
First quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.26 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: CN¥2.41b (up 10% from 1Q 2020). Net income: CN¥286.2m (up 4.1% from 1Q 2020). Profit margin: 12% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 19
Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥1.01 in FY 2019) The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: CN¥8.50b (down 9.3% from FY 2019). Net income: CN¥1.01b (down 4.7% from FY 2019). Profit margin: 12% (in line with FY 2019). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Announcement • Feb 19
China Resources Double-Crane Pharmaceutical Plans to Invest in Zhejiang Biotech Firm China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHSE:600062) said it plans to invest CNY 258.5 million ($39.97 million) in Zhejiang Biotech Firm for 33.3% stake. Is New 90 Day High Low • Jan 26
New 90-day low: CN¥11.83 The company is down 6.0% from its price of CN¥12.60 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥23.25 per share. Announcement • Jan 21
China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021 China Resources Double-Crane Pharmaceutical Co.,Ltd. announced that they will report fiscal year 2020 results on Mar 19, 2021 Is New 90 Day High Low • Dec 30
New 90-day low: CN¥11.90 The company is down 6.0% from its price of CN¥12.65 on 30 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Is New 90 Day High Low • Dec 11
New 90-day low: CN¥12.04 The company is down 6.0% from its price of CN¥12.82 on 11 September 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also down 6.0% over the same period. Is New 90 Day High Low • Nov 25
New 90-day low: CN¥12.51 The company is down 7.0% from its price of CN¥13.40 on 27 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 10.0% over the same period. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥1.01b, down 3.2% from the prior year. Total revenue was CN¥8.35b over the last 12 months, down 11% from the prior year. Is New 90 Day High Low • Oct 26
New 90-day low: CN¥12.62 The company is down 9.0% from its price of CN¥13.81 on 28 July 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥15.32 per share. Is New 90 Day High Low • Sep 29
New 90-day low: CN¥12.77 The company is down 4.0% from its price of CN¥13.36 on 01 July 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥15.32 per share. Announcement • Jul 09
China Resources Double-Crane Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 25, 2020 China Resources Double-Crane Pharmaceutical Co.,Ltd. announced that they will report first half, 2020 results on Aug 25, 2020 
